New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2012
16:33 EDTGILD, GNTX, EBAY, GSK, HGSI, TUMI, SPLK, DD, TRV, VZ, BACOn The Fly: Closing Wrap
Stocks on Wall Street were lower, as disappointing economic data overshadowed earnings that were largely better than expected. Stock futures were higher in early trading but weakened following disappointing jobless claims data and a rumor the sovereign debt of France would lose its AAA rating. When the French rumor went unfounded the market moved higher, but just temporarily. The averages stalled again after existing home sales data for March showed a decline versus an expected increase but gathered once more to move back into positive territory. As the day progressed and the European markets closed lower, the averages lost any momentum they'd found and fell back into negative ground. For the remainder of the day the market drifted in the red as investors prepared for the next round of corporate earnings reports... ECONOMIC EVENTS: In the U.S., more jobless claims applications were filed than forecast, with the figure hitting 386,000. Sales of previously owned homes in March unexpectedly fell 2.6% to a 4.48M annual rate from 4.6M in February. Forecasts had called for an increase to 4.61M. In Europe, Spain was able to sell more bonds than expected but at higher yields, leaving mixed impressions among investors... COMPANY NEWS: Bank of America (BAC) posted Q1 adjusted results that beat consensus, but shares declined 1.68% to $8.77. Among other Dow components, Verizon (VZ) and Travelers (TRV) also reported earnings that exceeded expectations and both saw their shares rise following the reports, with Verizon gaining 1.30% to $38.15 and Travellers advancing 3.75% to $61.70. Du Pont (DD) was the fourth Dow name to beat on earnings, but shares fell 1.24% to $52.61... Meanwhile, data analysis software company Splunk (SPLK) and luxury luggage and briefcase maker Tumi Holdings (TUMI) both surged after debuting their IPOs on the Nasdaq. Splunk shares priced at $17 and ended the day at $35.48, while Tumi priced at $18 and closed at $26.50Ö MAJOR MOVERS: Among the notable gainers were Human Genome Sciences (HGSI), up $7, or 97.63%, to $14.17, after saying it had turned down an unsolicited $13 per share, or approximately $2.6B, buyout proposal from GlaxoSmithKline (GSK), and eBay (EBAY), up $4.75, or 13.24%, to $40.62, as the companyís sales and profits beat analyst estimates, led by growth in its PayPal online payments business. Noteworthy losers included Gentex (GNTX), down $4.07, or 16.01%, to $21.35, after its top-line miss continued to reinforce investor fears over slowing growth, and Achillion (ACHN), down $1.20, or 12.63%, to $8.30, with the decline attributed by Wells Fargo to positive data for Gilead's (GILD) oral hepatitis C combination treatmentÖ INDICES: The Dow lost $68.65, or 0.53%, to 12,964.10; the Nasdaq fell $23.89, or 0.79%, to 3,007.56; and the S&P 500 dropped $8.22, or 0.59%, to 1,376.92.
News For BAC;VZ;TRV;DD;SPLK;TUMI;HGSI;GSK;EBAY;GNTX;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
September 17, 2014
09:03 EDTDDTrian requested one DuPont board seat this summer, CNBC reports
Subscribe for More Information
08:22 EDTDDDuPont issues statement regarding Trian
In response to the letter from Trian Fund Management sent earlier this morning, DuPont issued the following statement: "Our board of directors and management team have taken firm action over several years that has delivered 220 percent total shareholder return since year-end 2008, compared to 144 percent for the S&P 500 during the same period, by aggressively deploying our leading science across the company, strengthening and fine-tuning our portfolio, and through disciplined capital allocation. The board and management team remain committed to executing on our strategic plan to drive growth and profitability. The recently announced first phase of our redesign initiative to drive down costs by $1 billion and embed greater efficiencies, together with the separation of Performance Chemicals and our $5 billion share repurchase program, reflect our board and management's commitment to enhance value for all DuPont shareholders. DuPont welcomes open communications with shareholders and values input toward our common goal of enhancing shareholder value. We speak and meet with shareholders frequently, and while it is our policy not to comment on discussions with specific shareholders, we have had a constructive dialogue with Trian."
07:39 EDTGSKMorningstar to hold a conference
Management Behind the Moat Conference to be held in Chicago on September 17-18.
07:00 EDTDDTrian Partners calls for further initiatives to optimize long-term value
Subscribe for More Information
06:54 EDTBACNY Attorney General announces NYC bank identity-theft ring takedown
Subscribe for More Information
06:53 EDTDDWhite House says companies taking steps to reduce HFCs emissions
The Obama Administration yesterday announced new private sector commitments and executive actions to reduce emissions of hydroflourocarbons, or HFCs, powerful greenhouse gases that contribute to climate change, the Shite House stated. Coca-Cola (KO) has set a goal for 100 percent of its newly purchased cold drink equipment to be HFC-free, .while DuPont (DD),, announced that its new products are anticipated to reduce greenhouse gas content of refrigerants by some 90M tons carbon dioxide equivalent in the U.S., and 245M tons worldwide by 2025, the White House noted. Honeywell (HON) plans to transition the majority of its high-GWP HFC production to new low-GWP production, while Johnson Controls (JCI) committed to using the lowest GWP option for each application that best fits the needs of its customers from the standpoint of safety, efficiency, reliability, availability, and economy, according to the White House Johnson Controls also commits to spend $50M over the next three years to develop new products and improve and expand its existing low-GWP portfolio.
06:51 EDTDDTrian Partners says DuPont should separate into GrowthCo and CyclicalCo/CashCo
Subscribe for More Information
06:06 EDTDDTrian Partners says DuPont's structure 'destroying shareholder value'
Trian Fund Management, L.P., whose investment funds beneficially own approximately $1.6B of the outstanding shares of DuPont, said it has sent a letter to the bomard analyzing how DuPontís conglomerate structure is destroying shareholder value. The letter and accompanying White Paper Summary also detail initiatives DuPont should take that Trian believes could significantly improve DuPontís financial performance and double the value of its common stock within three years. Trian plans to meet with DuPont shareholders to present its analysis and strongly recommends that the DuPont Board meet shareholders without management present to hear their views. In the letter, Trian said, "While we applaud the announced spin-off of Performance Chemicals, the Fresh Start initiative and the $5 billion share buyback authorization, we believe strongly that, by themselves, these moves are not enough to optimize shareholder value. We would have preferred to continue working privately with management and the Board, but it is now clear that the Board is not willing to hold management accountable for continuing underperformance and repeated failures to deliver promised revenue and earnings targets. Therefore, we can no longer be silent as DuPont continues to struggle to execute what we are convinced is a flawed business plan, especially as we have a solution that we believe could double the value of DuPontís shares over the next three years."
06:04 EDTGILDGilead's simtuzumab Phase 2 study for pancreatic cancer does not meet endpoint
Gilead announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2, in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, the addition of simtuzumab to gemcitabine did not significantly increase progression-free survival compared to placebo plus gemcitabine. There was no difference in adverse events between patients taking simtuzumab versus placebo. Simtuzumab is being evaluated in several ongoing Phase 2 trials, including for advanced colorectal cancer, myelofibrosis, as monotherapy for idiopathic pulmonary fibrosis, and for liver fibrosis. Other agents in Gileadís oncology pipeline are currently being evaluated in clinical trials for the treatment of pancreatic cancer.
05:58 EDTDDTrian wants DuPont to spin off agriculture, nutrition units, WSJ reports
Subscribe for More Information
September 16, 2014
16:00 EDTBACOptions Update; September 16, 2014
Subscribe for More Information
14:44 EDTBACVirginia AG files $1.15B lawsuit against banks that sold RMBS during crisis
Subscribe for More Information
13:15 EDTBACBank of America gives up $6B in revenue with new consumer strategy, Reuters says
Subscribe for More Information
11:54 EDTBACBank of America reportedly cutting jobs in NY, Houston, DealBreaker says
Subscribe for More Information
08:18 EDTVZFCC to hold a roundtable
Subscribe for More Information
07:43 EDTBACRBC Capital to hold a conference
Subscribe for More Information
07:33 EDTGSKMylan initiates Phase III clinical trials for Advair Diskus and Lantus
Mylan (MYL) announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (GKS) Advair Diskus and its insulin analog to Sanofi's (SNY) Lantus. In October Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
07:31 EDTGSKEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
06:42 EDTEBAYPayPal running ads against Apple Pay, Business Insider reports
Subscribe for More Information
06:03 EDTBACHuntington Bancshares completes acquisition of 24 Bank of America branches
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use